Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. [electronic resource]
Producer: 20011207Description: 1783-9 p. digitalISSN:- 1524-4636
- Apolipoprotein A-I -- biosynthesis
- Apolipoprotein A-II -- blood
- Arteriosclerosis -- drug therapy
- Cholesterol, HDL -- metabolism
- Dose-Response Relationship, Drug
- Double-Blind Method
- Gemfibrozil -- pharmacology
- Hepatocytes -- metabolism
- Humans
- Hypolipidemic Agents -- pharmacology
- Lipids -- blood
- Lipoproteins, HDL -- chemistry
- Niacin -- pharmacology
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.